Platelet count and dose, but not comorbidities, predict severe neutropenia in cabazitaxel-treated prostate cancer patients: A retrospective observational study.

Riaki Kataoka,Takeo Hata,Kouichi Hosomi,Atsushi Hirata, Emi Goto,Masami Nishihara,Teruo Inamoto,Haruhito Azuma,Masashi Neo

International journal of clinical pharmacology and therapeutics（2023）

引用 0|浏览1

暂无评分

摘要

Comorbidities such as hypertension, dyslipidemia, diabetes mellitus, cerebrovascular disease, chronic kidney disease, liver dysfunction, and cardiac disease did not affect the incidence of severe neutropenia in patients receiving cabazitaxel. The baseline platelet count and the dose of cabazitaxel were also suggested to be markers for the development of severe neutropenia.

查看译文

关键词

severe neutropenia,prostate cancer patients,platelet count,cabazitaxel-treated

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要